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ABSTRACT Amiodarone is a drug used in the treatment of cardiac arrhythmias and is believed to have a persistent
interaction with cellular membranes. This study sought to examine the structure and location of amiodarone in a
membrane bilayer. Amiodarone has a high membrane partition coefficient on the order of 10'. Small angle x-ray
diffraction was used to determine the position of the iodine atoms of amiodarone in dipalmitoylphosphatidylcholine
(DPPC) lipid bilayers under conditions of low temperature and hydration where the DPPC bilayer is in the gel state.
The time-averaged position of the iodine atoms was determined to be -6 A from the center (terminal methyl region) of
the lipid bilayer. A dielectric constant of K- 2, which approximates that of the bilayer hydrocarbon core region, was
used in calculating a minimum energy structure for membrane-bound amiodarone. This calculated structure when
compared with the crystal structure of amiodarone demonstrated that amiodarone could assume a conformation in the
bilayer significantly different from that in the crystal. The results reported here are an attempt to correlate the position
of a membrane-active drug in a lipid bilayer with its time-averaged conformation. This type of analysis promises to be of
great use in the design of drugs with greater potency and higher specificity.
INTRODUCTION
Amiodarone is a drug used in the treatment of arrhythmia
(1). It has unusual pharmacokinetic properties character-
ized by an onset time with oral administration of 4-7 d and
a persistence of 30-45 d after treatment is discontinued
(1). Amiodarone interacts nonspecifically with a variety of
membrane sites such as sodium channels (2) and adrener-
gic receptors (3). This ligand contains two iodine atoms as
a part of its covalent structure (see Fig. 1). The high
electron density of the iodine atoms, in contrast to the lipid
bilayer, allows the time average position of amiodarone in
the membrane bilayer to be determined by small angle
x-ray diffraction.
In this study, the location of amiodarone in a synthetic
lipid bilayer was examined using x-ray diffraction. The
location was then used to assign a suitable dielectric
environment in which the crystallographic drug conforma-
tion could be energy minimized via the molecular mechan-
ics program MMP2 (4). Whereas a number of drug
conformation studies have been done, typically these stud-
ies have been carried out in vacuo using either the crystal-
lographic conformation of the drug (5), a default confor-
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mation based on standard bond lengths, bond angles, and
torsion angles (6), or by sampling the conformation space
defined by the torsion angles of a structure derived from
standard bond lengths and angles (7). Our study differs
from these types of studies in that we use a dielectric
environment similar to what exists in the lipid bilayer for
our analysis. We thereby more closely simulate the in vivo
environment of the drug yielding a more accurate picture
of the conformation of a drug in the bilayer. Knowledge of
both the location and conformation of a drug in the
membrane might shed light on the mechanism by which
membrane-active drugs such as amiodarone induce their
effects.
This report includes (a) a comparison of the partition
coefficients of amiodarone in different environments, (b)
the location of amiodarone within the membrane bilayer,
and (c) a calculated minimum-energy conformation of
amiodarone in a dielectric environment approximating the
membrane bilayer hydrocarbon core.
MATERIALS AND METHODS
Membrane Preparation and Measurement
of Partition Coefficients
The preparation of sarcoplasmic reticulum membranes from rabbit hind
leg skeletal muscle has been previously described (8, 9). Either sarcoplas-
mic reticulum membrane vesicles or octanol/buffer were used in the
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FIGURE 1 Crystal structure of amiodarone showing the
two iodine atoms that are part of the drugs covalent
structure.
measurement of partition coefficients as described in detail (Herbette,
L. G., Y. M. H. Vant Erve, and D. G. Rhodes, submitted for publication).
Membrane partition coefficients determined in DPPC vesicles were
measured by a filtration technique as previously reported (Herbette,
L. G., Y. M. H. Vant Erve, and D. G. Rhodes, submitted for publica-
tion).
Preparation of Lipid/Drug Samples
for X-Ray Diffraction
DPPC was dissolved in a 2:1 mixture of chloroform:methanol (2:1
vol/vol) and dried to a thin film using a stream of nitrogen gas. Buffer
(0.5 mM Hepes, 2.0 mM NaCl, 18.5 MM NaN2, pH 7.3) was then added
to provide a final lipid concentration of 5 mg/ml. This solution was
sonicated at 480C in a Branson B-22-4 ultrasonic bath for a brief time to
disperse the lipid. The resulting opalescent multilamellar vesicle suspen-
sion was stored at 40C before use. Amiodarone was dissolved in 95%
ethanol to a final concentration of 3.1 mM and stored in the dark until
use. Oriented multilamellar samples for x-ray diffraction were prepared
using the "spin-dry" procedure described previously (11, 12). For control
experiments, 50 ;d of DPPC lipid vesicle suspension (-250 Mg) was
introduced into a Lucite sedimentation cell. Amiodarone was incorpo-
rated by incubating 50 gl of DPPC vesicles with 0.5 Ml or 1.00 Ml of the
stock amiodarone solution. The equilibrated amiodarone: vesicle suspen-
sion was then added to the sedimentation cells. The samples were
centrifuged at 30C for 30 min at 85,000 g in a SW28 rotor (Beckman
Instruments, Inc., Fullerton, CA) to pellet the lipids onto aluminum foil.
These pellets were then dried during centrifugation at 45,000 g for 6 h as
previously described (12). The resulting dried lipid films were then
mounted on curved glass holders and equilibrated at 40C and 66% relative
humidity overnight to form partially dehydrated multilayers before x-ray
exposure.
X-Ray Diffraction Procedures
Small Angle Studies. All x-ray diffraction experiments using lipid
bilayers were carried out using an RU-3 x-ray generator (Rigaku/USA
Inc., Danvers, MA), equipped with a camera utilizing a single vertical
Franks' mirror as previously described in detail (13). The diffraction
patterns were collected at 80C on either x-ray film (Kodak NS-5T) or a
Braun position-sensitive proportional counting gas flow detector (PSPC)
(Innovative Technology Inc., South Hamilton, MA).
Diffraction samples were equilibrated to different relative humidities
in a range of 13-66% in sealed containers at 8°C (13). Under these
conditions of humidity and temperature the DPPC bilayer remained in
the gel state. For x-ray film experiments a vacuum path was used with a
specimen to film distance of 105 mm. Detector experiments used a helium
path for specimen to detector distances of 120 mm and an air path for
specimen to detector distances of 80 mm. For data collected on x-ray film,
relative intensities for the diffraction orders were obtained by scanning
with a Zeineh model SL-2DUV soft laser scanning densitometer (Biomed
Instruments Inc., Fullerton, CA) as previously described (13). Data
collected on the PSPC detector was integrated directly from computer
plots by computing areas under the reflections. Data reduction (back-
ground and other geometrical corrections) for either mode of data
collection has been described (13). Structure factors were phased by
swelling experiments (14) using the algorithm reported by Stamatoff and
Krimm (15).
Small Molecule Crystallographic Studies. The crystal structure of
amiodarone has been solved by Luft and Cody (16). To verify amiodarone
structural integrity we redetermined the crystal structure of amiodarone.
The amiodarone crystallization was performed out of ethanol. The
selected crystal was acicular measuring 0.3 x 0.1 x 0.1 mm. All
diffraction was collected using a TEXRAY/Rigaku system equipped
with an RU-200 generator, AFC-5 diffractometer, and TEXRAY control
software. The entire system was obtained from Molecular Structures
Corp., College Station, TX. Intensity data were collected to sin 0/, -
0.56 by measuring counts at peak positions, and background corrected
using counts collected at Aw ±0.40. Cell constants were determined by
fitting 20 data points, 20° s 20 < 340. Sample degradation and orienta-
tion were monitored by measuring the intensity of three standard
reflections every 150 data points. The crystal structure was solved by
direct methods using the TEXSAN package of programs (Molecular
Structures Corp.), including MITHRIL.
Characterization of Amiodarone
by UV Spectroscopy
UV spectroscopy was used to quantify the amount of amiodarone
incorporated into DPPC samples and to verify that the structure of
amiodarone did not change as a result of x-ray exposure. Spectroscopic
measurements were carried out on a model 250 spectrophotometer
(Gilford Instrument Laboratories Inc., Oberlin, OH) equipped with a
model 250 wavelength scanner. All samples were dissolved in redistilled
chloroform, which was used as a reference blank. To verify that the
membrane incorporated amiodarone was intact after x-ray exposure, we
extracted multilamellar membrane samples containing amiodarone with
500 Ml of chloroform and scanned from 245 to 360 nm. The resulting
absorption spectra were then compared with spectra obtained from stock
solutions of amiodarone and lipid as well as spectra of solubilized thin
films of lipid with and without amiodarone scanned over the same
wavelength range. The amount of amiodarone incorporated into these
samples was quantified spectrophotometrically by measuring absorbance
at the 310 nm absorbance peak of amiodarone (E310 - 3,030 M- cm-').
The measured absorbance was plotted against standard curves obtained
from amiodarone and amiodarone + 200Mug DPPC. Both standard curves
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were linear in the concentration range measured and gave identical values
for '310. The amount of lipid in each x-ray sample was determined by
exhaustive acid hydrolysis of the samples followed by measurement of
total phosphate (12).
Absolute Electron Density
Scale Determination
The average electron densities for the DPPC headgroups, fatty acyl
methylene segments, terminal methyl region, and water were calculated
to be 0.430 (0.46 for the phosphate moiety and 0.42 for the glycerol
moiety), 0.260, 0.196, and 0.334, respectively, utilizing previously
accepted values deemed reasonable (17, 18). A step-function equivalent
profile was fitted to the continuous experimental electron density profile
structure of DPPC at a resolution of 7.5 A. An average electron density
was assigned to the steps corresponding to the headgroup phosphate and
methylene region of the profile. The resulting scale indicated that for the
pure water steps outside the headgroup region the average electron
density was the same as that calculated, 0.334 e/A3. Therefore, the
assigned absolute electron density scale for the profile structure of pure
DPPC was considered reasonable. The profile structure for DPPC +
amiodarone was empirically compared with the DPPC profile structure
and assigned an absolute scale based on the two steps within the
step-function equivalent profile corresponding to the phospholipid head-
group region (phosphate moiety) and the pure water layer. The additional
electron density in the hydrocarbon core region of the membrane was
attributed to the amiodarone molecule with two iodine atoms. This
additional electron density was calculated from the assigned absolute
electron density scale and compared with the electron density determined
from the composition, i.e., the measured lipid to amiodarone molar ratio.
These two independent approaches gave the same assignment for the
absolute electron density of the iodine in the experimental profile
structure of DPPC + amiodarone. It is possible to assign absolute
electron densities by comparing electron density profiles of varying
drug/lipid ratios. Our method of using one drug/lipid ratio that was
spectrophotometrically quantified allowed the use of a low drug concen-
tration while insuring sufficient signal to noise that the position of the
drug could be determined unambiguously.
Molecular Modeling
The molecular mechanics program MMP2 (4), which assumes a homo-
genous environment for the molecule, was used to estimate the minimum
energy conformation of amiodarone in the bilayer interior. We deemed
this to be an acceptable approximation as the position amiodarone
assumes in the bilayer is far enough removed from the hydrocarbon
core/water interface that the molecule is surrounded by a homogeneous
environment of lipid acyl chains. Because several needed parameters
(particularly those involving iodine) are not in the MMP2 parameter set,
some parameters based on published data were used (19-21). Crystallo-
graphic coordinates were used as initial coordinates for the calculation.
To determine the minimum energy conformation, energy minima were
computed in a dielectric range from K- 2 to K - 80 using the crystal
structure for the initial coordinates. To account for the possibility that the
computed minimum energy conformations were not global minima,
conformation space for the starting coordinates was sampled using the
"dihedral driver" option of MMP2 at K - 2 to generate several energy-
minimized sets of conformations related to the initial crystallographic
conformation. These conformations were generated by torsion in steps of
600 about the C4-C5, C13-C14, C14-C16, C19-024, and 024-C25
bonds (see Fig. 1). The total energies for the energy-minimized structures
derived from the crystal structure and the dihedral driver option were
compared to determine whether a given structure was a local minimum.
The conformation with the lowest total energy was deemed to be the
"global" minimum in this study. The structure of lowest energy was
compared with the crystal structure as follows. The benzofuran rings of
the two structures were mapped onto each other. Because these are planar
rigid structures their oonformations do not change on energy minimiza-
tion and can therefore be used to define a common origin for the two
structures. Using the common origin defined by the superimposed
benzofuran rings, the RMS deviation of nonhydrogen atoms between the
two structures was calculated. The change in the angle of orientation of
the benzofuran and 3,5-diiodophenyl ring was determined by measuring
the torsion angle between atoms C5 and C 13 of the benzofuran and atoms
C16 and C17 of the iodophenyl moiety.
Materials
All chemicals used were reagent grade with aqueous solutions made using
glass distilled deionized water. Unlabeled and 1"I-amiodarone were gifts
from s.a. Labaz-Sanofi n.v., Brussels, Belgium, made possible by P.
Chatelain. Labeled amiodarone was stored at - 120C and unlabeled
amiodarone was stored at 40C. All drug stocks were protected from light
at all times. DPPC was obtained from Avanti Polar Lipids, Birmingham,
AL, and was used without further purification. TLC analysis of these
lipids yielded a single spot.
The molecular graphics package Chem-X (developed and distributed
by Chemical Design Limited, Oxford, UK) was used to display the
conformation of amiodarone in a membrane and in a crystal and to obtain
some geometric parameters.
RESULTS
Partition Coefficients
Membrane partition coefficients for amiodarone were
obtained in light sarcoplasmic reticulum membrane prepa-
rations and octanol/buffer (Table I). The membrane
partition coefficient for DPPC below the thermal phase
transition (Tm) was 20,000 ± 5,900, whereas the partition
coefficient above the thermal phase transition was at least
two orders of magnitude greater, -2,000,000. Above the
Tm, the extremely high amiodarone lipid binding affinity,
and the resultant low free ligand concentration, makes
determination of the exact partition coefficient value diffi-
cult. The partition coefficients in the sarcoplasmic reticu-
lum membrane compare favorably with those determined
in DPPC vesicles above the thermal phase transition.
X-Ray Crystallography of Amiodarone
Amiodarone crystallized in a monoclinic system with space
group P21/a. The lattice parameters were a = 9.1739, b =
17.104, c = 17.138, and beta = 98.3840. The lattice
parameters reported here match those reported by Luft
and Cody (16). 1,732 reflections were recorded giving a
final structure with an r-fit of 0.053. During the course of
the experiment the intensities of the reference reflections
changed by <5%. Fig. 1 shows the crystal structure of
amiodarone. No solvent was present in the crystal unit
cell.
TABLE I
AMIODARONE PARTITION COEFFICIENTS
LSR/buffer 760,000 ± 93,000
Octanol/buffer 350 ± 30
DPPC/buffer (2-C) 20,000 ± 5,900*
DPPC/buffer (>420C) >2,000,000
*Measurement done using the filtration technique.
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Scattering Profiles and Calculated Electron
Density Profiles
Fig. 2 shows the scattering profiles observed for both
DPPC and DPPC with amiodarone at 80C and 13%
relative humidity. At this humidity the DPPC multilayer
unit cell repeat distance was 57.6 A whereas the unit cell
repeat distance for DPPC with amiodarone was 60.6 A.
The highest order reflection observed in the experiment
was I(h = 12). Only reflections through I(h = 8) could be
unambiguously phased. The calculated electron density
profiles corresponding to I(h = 8) for DPPC and DPPC
with amiodarone are shown in Fig. 3 The overall shapes of
the two electron density profiles are similar. Both profiles
are beginning to resolve the glycerol backbone from the
phosphate of the phosphatidylcholine headgroup. The
additional electron density, attributed to the amiodarone
molecule with two iodine atoms on the 3,5-diiodophenyl
ring, is indicated by the area of increased electron density
at ±6 A from the terminal methyl region of the bilayer.
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FIGURE 3 Electron density profile structures for (A) DPPC and (B)
DPPC with amiodarone for diffraction patterns corresponding to Fig. 2,
A and B, respectively.
Model Calculations of Absolute
Electron Densities
The electron density profiles were placed on an absolute
electron density scale as shown in Fig. 4. This scale was
consistent with the measured composition of the DPPC/
amiodarone samples (1 amiodarone [2 iodine atoms] per
1 5 lipids). Thus, the assignment of the additional electron
density (centered at ±6 A from the terminal methyl
region of the hydrocarbon core) to the iodine atoms of the
amiodarone must be correct. The size of the molecule is
e/A3
0
FIGURE 2 X-ray diffraction patterns from (A) DPPC at 13% relative -40 -20 0 20 40
humidity and (B) DPPC + amiodarone at 13% relative humidity taken x(A)
on a one-dimensional position sensitive x-ray detector. Up to I(h = 12)
was observed. Unit cell repeat distances were 57.60 and 60.56 A, FIGURE 4 Step function equivalent profiles to the experimental profile
respectively. structures of Fig. 3 placed on an absolute electron density scale.
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such that two molecules can span the hydrocarbon core
region of the bilayer (Fig. 5 B). Therefore, the overall
increase of electron density in the hydrocarbon core region
of the membrane is probably due to the presence of
amiodarone.
Model Calculations of the Membrane
Minimum Energy Conformation
of Amiodarone
Minimum energy conformations for amiodarone in a
DPPC membrane bilayer were calculated for several dif-
ferent values of dielectric constant, using MMP2, which
assumes a homogeneous environment for the molecule.
Crystal structure data were used for starting coordinates,
and calculations were carried out for dielectric constants
ranging from K = 2, which corresponds to the hydrocarbon
region of the membrane, to K = 80, which corresponds to
water. Because electrostatic interactions made only minor
contributions to the total energy of the structure, increas-
ing the dielectric constant from K = 2 to K = 80 had a
negligible effect on the calculated conformation. The dihe-
dral driver option of MMP2 was used to generate 30 sets of
starting coordinates, which sampled a wide range of con-
formation space. Minimum energy structures were calcu-
lated for all of these starting coordinants at a dielectric
constant of K = 2. The computed minimum energy struc-
tures of several of these were nearly identical, with calcu-
lated total energies that differed by <1.5 kcal/mol. The
conformation taken as the "global" minimum by virtue of
having the lowest total energy was generated by a 600
torsion about the 024-C25 bond.
Minimization produced pronounced changes in the
bilayer structure of the drug as compared with the crystal-
lographic structure. The lowest energy structure showed an
overall RMS shift of 1.36 A from the initial crystallo-
graphic structure. The largest change was a reorientation
of the benzofuran ring with respect to the central 3,5-
diiodophenyl ring. In the crystal structure, the torsion
angle between these two rings was 81.840. In the mini-
mized bilayer structure of the drug, the benzofuran ring
was more nearly parallel to the 3,5-diiodophenyl ring with
a torsion angle of 40.850 as shown in Fig. 5 A. Shifts in the
conformation of other regions of the molecule were not as
TABLE II
ATOMIC COORDINATES FOR THE CRYSTAL STRUCTURE AND MEMBRANE MINIMUM ENERGY STRUCTURE
OF AMIODARONE (A)
Amiodarone crystal coordinates Amiodarone minimum energy coordinates
X Y Z X Y Z
C1 1.24808 4.34290 2.60845 C1 1.34247 5.87277 2.55609
C2 0.58147 5.55359 3.30018 C2 0.38936 6.01078 3.75125
C3 -0.72720 5.92698 2.69747 C3 -1.07323 6.25415 3.34011
C4 -1.84786 4.93349 3.03188 C4 -1.75415 5.01382 2.73082
C5 -3.13561 5.29959 2.30601 C5 -3.15614 5.34503 2.26823
06 -3.91560 6.13211 3.11397 06 -3.92815 6.09455 3.10279
C7 -4.98860 6.47492 2.28955 C7 -4.97543 6.46247 2.33646
C8 -6.08052 7.24260 2.68044 C8 -6.05802 7.26572 2.69404
C9 -7.02991 7.51878 1.78078 C9 -7.04516 7.51582 1.73987
CIO -6.92669 6.97826 0.48887 CIO -6.94251 6.96420 0.45734
Cll -5.87481 6.17363 0.09614 Cll -5.85493 6.15955 0.10738
C12 -4.87362 5.92967 1.02954 C12 -4.86096 5.91407 1.05889
C13 -3.65609 5.17315 1.05551 C13 -3.71961 5.18840 1.04544
C14 -3.00956 4.61877 -0.10876 C14 -3.26196 4.52185 -0.05206
015 -3.24248 5.04463 -1.21740 015 -3.63144 4.88677 -1.14740
C16 -1.91353 3.54909 0.00353 C16 -2.44250 3.43047 0.00542
C17 -0.79552 3.65432 -0.80687 C17 -1.83017 2.94466 -1.15868
C18 0.21753 2.70956 -0.75431 C18 -1.01997 1.80646 -1.15427
C19 0.04377 1.59461 0.11455 C19 -0.74107 1.10754 0.03614
C20 -1.10220 1.44408 0.87077 C20 -1.48973 1.49293 1.15760
C21 -2.10981 2.44405 0.81385 C21 -2.29820 2.63588 1.14420
122 1.90042 3.03591 -1.93275 I22 -0.27547 1.12585 -3.01273
I23 -1.41687 -0.25227 2.02483 123 -1.50810 0.29212 2.89006
024 1.03264 0.60918 0.14680 024 -0.01028 -0.04870 0.04625
C25 2.01750 0.82920 1.16040 C25 1.40413 0.07717 0.03059
C26 2.77725 -0.48963 1.39033 C26 1.99572 0.84630 1.22369
N27 3.66120 -0.91803 0.23475 N27 1.81081 0.24054 2.54558
C28 2.89793 - 1.50838 -0.89863 C28 2.43030 1.01666 3.62901
C29 2.00395 -2.62657 -0.50469 C29 1.96976 2.47954 3.70898
C30 4.59476 0.16888 -0.18014 C30 2.14719 -1.18573 2.62790
C31 5.74397 -0.35563 -0.98583 C31 3.60188 -1.55047 2.29818
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pronounced but were significant. Table II lists the crystal-
lographic coordinates of amiodarone along with those of
the energy-minimized conformation of amiodarone in the
DPPC lipid bilayer.
DISCUSSION
Location of Amiodarone in a Lipid Bilayer
The electron density profile structures in Fig. 3 indicate
additional electron density centered at x = ±6 A from the
central region of the lipid bilayer in the presence of
amiodarone. Model calculations indicate that this addi-
tional electron density arises from the amiodarone mole-
cule with two iodine atoms covalently bonded to the phenyl
ring of amiodarone. From these data, amiodarone is
located within the hydrocarbon core of the membrane
bilayer near the terminal methyl region, as schematically
portrayed in Fig. 5 B. As previously discussed (22), the
appearance of additional electron density in a profile
structure seen in an x-ray diffraction experiment using a
A
B
FIGURE 5 (A) The minimum energy structure of amiodarone calcu-
lated in a low dielectric medium with the program MMP2 superimposed
on the crystal structure of the drug. The solid bonds indicate the
energy-minimized structure. The crystal structure is indicated by dashed
bonds. (B) Amiodarone incorporated into a membrane bilayer showing
the position of the iodine atoms relative to the acyl chains and the size of
the molecule relative to the hydrocarbon core region.
drug with a single electron dense atom substitution, cannot
distinguish between the following cases. (a) Perturbations
of the electron density profile structure of the drug/lipid
complex due solely to the presence of the drug's electron
dense atom. (b) Perturbations of the electron density
profile structure due to changes in the lipid bilayer struc-
ture resulting from the drug's presence.
A more definitive experiment using two different halo-
genated analogues of the same drug (e.g., bromine vs.
iodine) could distinguish between the above two situations
(22). However, in our studies, the DPPC profile structures
in the presence and absence of amiodarone have similar
unit cell repeats, and similar phospholipid headgroup
separations. With model calculations that indicate a con-
sistency between the absolute electron densities within the
profile structure and its composition, the conclusions
regarding the location of amiodarone appear to be correct.
The conclusion that amiodarone is located near the
center of the hydrocarbon core region of the bilayer below
the thermal phase transition and at relatively low hydra-
tion is in accord with that reported by Chatelain et al. (23).
Chatelain et al. (23) reported that amiodarone serves to
decrease membrane fluidity as would be expected for a
molecule which specifically interacts with the lipid acyl
chains. Jendrasiak et al. (24) have proposed, on the basis of
multinuclear NMR studies, that amiodarone assumes a
location in the bilayer near the phospholipid headgroup
region of a membrane bilayer. This study differed from our
study in that Jendrasiak et al. (24) used the charged lipid
species phosphatidic acid and stearylamine in fully
hydrated liposomes with a lipid to amiodarone molar ratio
of 3:2.
Recent theoretical studies indicate the possibility that
drugs partitioning into a membrane bilayer will assume
discrete preferred locations (25). The theory predicts that
a molecule will assume a location either near the hydrocar-
bon core/water interface or near the terminal methyl
region of the membrane bilayer. The molecule's lipophilici-
ty, in part, determines which of these two positions the
molecule will assume. This theoretical model appears to
hold true for the drug examined in this study. Amiodarone
has a high lipophilicity and as predicted is located near the
terminal methyl groups of the fatty acyl chains. Lipophilic-
ity is, however, probably only one of several parameters
responsible for a drug's location, orientation, and confor-
mation in a membrane bilayer. The physical state of the
lipid chains and the degree of hydration of the membrane
bilayer may also be important parameters influencing the
location of a drug in a membrane bilayer.
Correlation of Location and
Partition Coefficient
Intuitively one would predict that a drug with a membrane
partition coefficient as large as amiodarone's would be
located deep within the membrane bilayer. The position of
amiodarone as determined by small angle x-ray scattering
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is in accord with this idea. The high membrane partition
coefficient for amiodarone is not consistent with its octa-
nol/buffer partition coefficient. This is similar to the
results in Herbette et al. (26) in which the authors
demonstrated that the octanol/buffer (Table I) partition
coefficient is not a good indicator of the partitioning of
drug into sarcoplasmic reticulum membranes.
Chatelain and Laruel (27) have previously determined
the partition coefficient of both neutral and protonated
amiodarone. Whereas the value they observed for the
partitioning of neutral amiodarone is in accord with our
values, at the pH used in our studies (pH 7.0) amiodarone
should be fully protonated. They determined a partition
coefficient of 16,500 ± 1,400 for protonated amiodarone in
total lipids extracted from erythrocyte ghosts. We, on the
other hand, determined a value of 760,000 ± 93,000 for
amiodarone partitioning into light sarcoplasmic reticulum
(LSR) membranes. We believe the discrepancy between
the two sets of partition coefficients to result from two
factors. First, in the Chatelain and Laruel study a high
lipid amount was used. This can lead to an excessive
depletion of the amount of drug in the aqueous pool
causing nonequilibrium conditions. Such a condition could
then lead to an underestimate of the partition coefficient
for the drug being studied. Secondly, we determined our
partition coefficients in a different membrane system.
Because we used both a concentration of lipid much lower
than that used by Chatelain and Laruel and different lipid
systems, we feel that the partition coefficients reported by
us for amiodarone are more valid.
Correlation of Location and Structure
Only part of the total energy that specifies a molecular
conformation stems from implicit molecular parameters
(bond stretch, bend, etc.), the remainder arises from
packing constraints, solvent effects, and other environ-
mental variables. In the crystal form, a molecule's mini-
mum energy conformation is determined by an equilibrium
balance between packing constraints and molecular ener-
gies such as drug-drug interactions, which may perturb
the molecule's "implicit (in vacuo) conformation." In
addition, although the environment of a given molecule in a
crystal is exactly known by the symmetry of the unit cell,
this is not necessarily a uniform environment such as the
molecule would sense in a vacuum or (in the time average)
in a homogeneous environment such as a solution. Because
the bilayer center is thought to be a relatively uniform
environment, it should be possible to estimate the confor-
mation of amiodarone partitioned into the center of a
bilayer. This calculation necessarily ignores potential
packing constraints, essentially assuming the bilayer inte-
rior to be a homogeneous solution of "long chain alkane."
It is not surprising, therefore, that there are some differ-
ences between the computed minimum energy structure of
amiodarone in a bilayer and the "experimentally deter-
mined minimum energy structure" of amiodarone
obtained by crystallography (Fig. 5 A). Whereas the
effects of acyl chain packing on the conformation of the
amiodarone were not examined, we believe that the effect
of packing in a bilayer to be smaller than the effects of
packing experienced in a crystal. Molecular mechanics
calculations indicate that the minimum energy structure of
amiodarone in a lipid bilayer is significantly different from
the crystal structure having an overall RMS difference of
1.36 A due chiefly to the reorientation of the two rings of
amiodarone to become more planar. Although the absolute
(global) minimum energy conformation might be deter-
mined by refinement of this computation, this is a reason-
able structure for use in further discussions of the mem-
brane structure of amiodarone.
In a study by Ferreira et al (7) the conformation of
amiodarone at an air-water interface was examined. In this
study, an initial structure for amiodarone was created and
other structures generated by torsion about specific bonds.
These structures were then minimized in a dielectric
gradient and fitted to the air-water interface. They
reported that the preferred structures had the benzofuran
and iodophenyl rings roughly orthogonal. The MMP2
energy-minimized structure of amiodarone in a lipid
bilayer, in contrast, has the two rings in a more planar
orientation. The differences observed between our struc-
tures and the structures reported by Ferreira et al. are most
likely due to differences in the energy minimization meth-
ods by which these structures were obtained.
The resolution of the small angle x-ray diffraction
experiments was not high enough to determine whether the
iodine atoms were lying in the same plane. Therefore, it
was not possible to experimentally determine the orienta-
tion of the drug in the membrane. However, orienting the
whole amiodarone molecule such that the long axis of the
amiodarone is parallel to the acyl chain could explain the
generally elevated electron density observed in the acyl
chain region of the bilayer. If the long axis of the amioda-
rone were perpendicular to the acyl chains, the drug would
not span enough of the hydrocarbon core to account for the
elevated electron density seen if the drug is localized to a
discrete position in the bilayer as indicated by the diffrac-
tion results. Makriyannis et al. (28) have demonstrated
that it is possible to determine the orientation of a deuter-
ated molecule in a lipid membrane. An NMR or neutron
diffraction approach could potentially be utilized here to
determine the orientation of amiodarone in the membrane
bilayer. Coupled with knowledge of the location and
conformation of a molecule, knowledge of the orientation
of a molecule in a lipid bilayer would allow a complete
understanding of the molecular interactions of a drug and
a bilayer.
SUMMARY
Clearly, if one wishes to understand the pharmacology of a
membrane-active drug, a determination of a number of
molecular parameters is necessary. One should know the
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location and orientation of the drug in the membrane as
well as the conformation the drug assumes in this environ-
ment. This study sought to address two of these questions,
"what is the location of the drug"? and "what is it's
predicted energy minimized membrane conformation"?
We have been able to localize the position of the iodine
atoms of amiodarone to 6 A from the center of a mem-
brane bilayer. It is much more difficult to determine the
conformation of the drug in the bilayer. Based on the
crystal structure of the drug and knowledge of its location
in a membrane bilayer, a minimum energy structure in a
dielectric environment similar to the interior of the bilayer
was determined. This established that, for amiodarone, the
crystal and energy-minimized membrane bilayer struc-
tures were significantly different. The large scale changes
were due almost solely to changes in the orientation of the
two ring structures. The effects of the acyl chain environ-
ment on the conformation of amiodarone was beyond the
scope of this analysis but undoubtedly is of importance for
a complete understanding of the drug's pharmacology, as is
an accurate determination of the orientation of the drug in
the membrane bilayer. These results are a first step
towards an understanding of the complete interaction
between lipid membranes and a membrane-active drug. As
such they may provide valuable insight and direction for
future studies in this area.
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